Cargando…
Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
BACKGROUND: In gout, long-term urate-lowering therapy (ULT) promotes dissolution of tissue urate crystal deposits. However, no studies using combined xanthine oxidase inhibition and uricosuric ULT have focused on clinical outcomes or adverse events (AEs) beyond 12 months of therapy. Our objective in...
Autores principales: | Dalbeth, Nicola, Jones, Graeme, Terkeltaub, Robert, Khanna, Dinesh, Fung, Maple, Baumgartner, Scott, Perez-Ruiz, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322285/ https://www.ncbi.nlm.nih.gov/pubmed/30616614 http://dx.doi.org/10.1186/s13075-018-1788-4 |
Ejemplares similares
-
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017) -
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019) -
Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
por: Frassetto, Lynda Ann, et al.
Publicado: (2016) -
Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019) -
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
por: Bardin, Thomas, et al.
Publicado: (2017)